Target intelligence / Profile preview

Dynactin associated protein pseudogene 2 (DYNAPP2)

Target
DYNAPP2
Molecular classification
Other (Pseudogene)
01

Overview

Dynactin associated protein pseudogene 2 (DYNAPP2) is annotated as a pseudogene, meaning it bears sequence similarity to "dynactin associated protein" genes but is considered nonfunctional due to disruptive mutations in its sequence[1][2][4]. In general, pseudogenes were long viewed as nonfunctional relics of evolution but are now known in some cases to participate in regulation of gene expression through mechanisms such as acting as decoys for microRNAs (competing endogenous RNAs, or ceRNAs) or potentially producing regulatory non-coding RNAs[2][3]. However, there is no evidence that DYNAPP2 itself is expressed or functional, or that it encodes a protein, or acts as a receptor, enzyme, or any other classical therapeutic target. There is no data reporting DYNAPP2 as a biomarker, safety concern, or drug target. Pseudogenes in general may have context-dependent regulatory effects, but unless explicitly supported by experimental evidence (which does not exist for DYNAPP2), DYNAPP2 should be considered a nonfunctional genomic element with no established protein product or therapeutic relevance[2][3][5].

Other names
DYNAP pseudogene 2DYNAPP2dynactin associated protein pseudogene
02

Biological functions

May act as a non-coding RNAMay serve as a microRNA decoy (ceRNA)Potential for regulatory ncRNA activity (no direct evidence specific to DYNAPP2)
03

Disease associations

Pseudogenes can play regulatory roles and be associated with diseases as decoys or regulatorsNo reports directly implicating DYNAPP2 in specific diseases

Beyond the preview

Go deeper on Dynactin associated protein pseudogene 2 (DYNAPP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynactin associated protein pseudogene 2 (DYNAPP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call